Rivaroxaban submitted for wider approval in EU

04/12/2012 | Fox Business

Bayer is seeking EU authorization to market anti-coagulant rivaroxaban as a pulmonary embolism therapy. Partner Johnson & Johnson will apply this quarter for FDA approval of rivaroxaban to treat venous thromboembolism, a Bayer spokeswoman said.

View Full Article in:

Fox Business

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX